BioSpace News Archive

Quest Diagnostics announced today that it received the Gold Award in the 2018 Best Employers for Healthy Lifestyles awards from the National Business Group on Health (NBGH).

Axonics Modulation Technologies, Inc. announced today that it has filed an S-1 registration statement with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed public offering of its common stock.

Oblique Therapeutics today announced that it will present new promising preclinical data for the drug candidate OT-1096 in triple-negative breast cancer (TNBC) at the largest oncology congress in Europe, the European Society for Medical Oncology (ESMO), held 19-23 October in Munich, Germany.

London area doctors can now offer exclusive, limited-membership model to patients

Licence amendments for Canopy Growth Corporation’s wholly-owned subsidiary, BC Tweed Joint Venture Inc. (BC Tweed) and its majority-owned joint venture, Les Serres Vert Cannabis Inc. (Vert Cannabis) have been issued by Health Canada, collectively representing approximately 1.1 million sq. ft. of new greenhouse growing space on Canada’s largest cannabis platform.

Cerevance today announced that it has appointed Ted Hibben as Chief Business Officer.

OmniLytics, Inc. announces today that the EPA has approved two new bacteriophage products, AgriPhage™-Fire Blight and AgriPhage™-Citrus Canker, for the control of their namesake diseases.

European Medicines Agency (EMA) will begin review of the Marketing Authorisation Application (MAA) for Rhokiinsa® (netarsudil ophthalmic solution) 0.02%, currently marketed as Rhopressa® in the United States

Pivotal Phase 3 Data Included in ESMO Presidential Symposium and Official Press Program: KEYTRUDA® (pembrolizumab) as First-

If Approved, U.S. Pilot Study Anticipated to Commence in 4Q 2018